IRLAB progresses fully funded IRL757 study in Parkinson’s Disease in partnership with MSRD

Gothenburg, Sweden, October 2, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that its collaborator, – the McQuade Center for Strategic Research and Development, LLC (MSRD) – has issued a payment of USD 4 million to further advance the drug candidate IRL757 into a clinical safety, tolerability and Signal Finding Study in patients with Parkinson’s disease who experience apathy. The first patients are expected to be enrolled before the end of 2025.

IRLAB is granted a patent strengthening the market exclusivity of the drug candidate mesdopetam in China

Change in number of shares and votes in IRLAB Therapeutics AB